MedTrace Logo

Adaptive Immune Response to COVID-19 Vaccination

NCT04826770 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 70

Last updated 2023-10-03

No results posted yet for this study

Summary

AICOVI (Adaptive Immune Response to COVID-19 Vaccination) is a prospective clinical cohort study aiming at studying the kinetics of vaccine-specific antibody production after COVID-19 vaccination in health care workers.

Conditions

  • SARS-CoV-2 Vaccination

Interventions

DRUG

BNT162b2

vaccination against COVID-19

DRUG

AZD 1222

vaccination against COVID-19

DRUG

mRNA-1273

vaccination against COVID-19

Sponsors & Collaborators

  • University Medicine Greifswald

    lead OTHER

Principal Investigators

  • Barbara M. Bröker, Prof. Dr. · University Medicine Greifswald, Dept. of Immunology

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-01-06
Primary Completion
2021-12-13
Completion
2023-12-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04826770 on ClinicalTrials.gov